LipimetiX Development, a biopharmaceutical joint venture between Capstone Therapeutics Corp. and LipimetiX, Inc., focuses on developing innovative drugs to treat refractory hypercholesterolemia, hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases. The company's core mission is to rapidly decrease arterial cholesterol content and inflammation through a novel class of drugs based on chimeric peptide mimetics technology.

Notable affiliated individuals include key scientists and executives from both founding companies. LipimetiX has garnered attention for its pioneering approach in the biopharmaceutical industry, achieving significant milestones in drug development. The company's impact lies in its potential to address critical unmet medical needs, offering new hope for patients with severe cholesterol-related conditions.